The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
751
Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26
Change from baseline in HbA1c was analyzed using mixed model repeated measures (MMRM) and includes fixed class effects of treatment, strata (pooled country, type of basal insulin, and age group), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. An unstructured covariance structure will be used to model the within-participant errors. The Efficacy estimand included data collected prior to permanent discontinuation of study drug through Week 26.
Time frame: Baseline, Week 26
Change From Baseline in HbA1c (Postprandial) at Week 26
Change from baseline in HbA1c postprandial was analyzed using (MMRM and includes fixed class effects of treatment, strata (pooled country, type of basal insulin, and age group), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. An unstructured covariance structure will be used to model the within-participant errors. The Efficacy estimand included data collected prior to permanent discontinuation of study drug through Week 26.
Time frame: Baseline, Week 26
Percentage of Participants With Documented Post-dose Hypoglycemic Events Within 1 and 2 Hours After the Prandial Dose
Documented post-dose hypoglycemia \<54 milligrams per deciliter (mg/dL) and ≤ 70 mg/dL that occurred 1 and 2 hours after prandial dose.
Time frame: Baseline through Week 26
Rate of Documented Post-dose Hypoglycemic Events Within 1 and 2 Hours After the Prandial Dose
Documented post-dose hypoglycemia event is an event of blood glucose of \< 54 mg/dL and ≤70 mg/dL that occurred within 1 and 2 hours after the prandial dose. The rate of documented hypoglycemia was estimated by a negative binomial regression including treatment and age group as independent variable and number of episodes as dependent variables with log (exposure/365.25 days) as the offset in the model.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Administered SC
University of Alabama Birmingham
Birmingham, Alabama, United States
University of Arizona
Tucson, Arizona, United States
Children's Hospital Los Angeles - Dept of Endocrinology
Los Angeles, California, United States
Stanford University School of Medicine - Division of Pediatric Endocrinology & Diabetes
Palo Alto, California, United States
Center of Excellence in Diabetes & Endocrinology
Sacramento, California, United States
Rady Childrens Hospital - San Diego
San Diego, California, United States
Barbara Davis Center
Aurora, Colorado, United States
Florida Hospital
Orlando, Florida, United States
Tallahassee Memorial HealthCare
Tallahassee, Florida, United States
University of South Florida Diabetes & Endocrinology Center
Tampa, Florida, United States
...and 101 more locations
Time frame: Baseline through Week 26
Percentage of Participants With Documented Hypoglycemic Events
Documented hypoglycemia is defined as \<54 mg/dL and ≤70 mg/dL, respectively.
Time frame: Baseline through Week 26
Rate of Documented Hypoglycemia Events
Documented hypoglycemia is defined as a hypoglycemic event of blood glucose of ≤70 mg/dL or \<54 mg/dL. The rate of documented hypoglycemia was estimated by negative binomial regression including treatment and age group as independent variables and number of episodes as dependent variable with log (exposure/365.25 days) as the offset in the model.
Time frame: Week 0 through Week 26
Rate of Severe Hypoglycemia
Severe hypoglycemia: during these episodes, participants have an altered mental status and cannot assist in their own care, may be semiconscious or unconscious, or experience coma with or without seizures, and require assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. The rate of severe hypoglycemia per 100 years was calculated as: 100 times the total number of severe hypoglycemia episodes within the period divided by total exposure (in year) for all participants within the treatment group.
Time frame: Week 0 through Week 26
Change From Baseline in Insulin Dose at Week 26
Change from baseline in insulin dose was analyzed using mixed model repeated measures (MMRM) and includes fixed class effects of treatment, strata (pooled country, type of basal insulin, age group, and HbA1c stratum (≤8.0%, \>8.0%)), baseline value, visit and treatment-by-visit interaction. An unstructured covariance structure was used to model the within-participant errors.
Time frame: Baseline, Week 26
Percentage of Participants With HbA1c < 7.0% and <7.5%
Percentage of participants with HbA1c \< 7.0% and \<7.5% was analyzed using a longitudinal logistic regression with repeated measurements conducted by a generalized linear mixed model including independent variables of treatment, baseline HbA1c value, visit, baseline HbA1c-by-visit interaction, and treatment-by-visit interaction. An unstructured covariance structure was used.
Time frame: Week 26
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values at Week 26
Change from baseline in 7-point SMBG values were analyzed using MMRM and includes fixed class effects of treatment, strata (pooled country, type of basal insulin, and age group, and HbA1c stratum (≤8.0%, \>8.0%)) baseline value, visit, and treatment-by-visit interaction. An unstructured covariance structure was used to model the within-participant errors.
Time frame: Baseline, Week 26